MAGNITUDE:
Study Review and Key Findings
A phase III randomized, placebo-controlled, double-blind study of niraparib plus
abiraterone acetate and prednisone versus abiraterone acetate and prednisone in
patients with metastatic prostate cancer
Kim Chi